Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al.

At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University of Washington) presented updated data from the JAVELIN Merkel 200 Part A registrational study. This study showed that at >2 year of follow-up, avelumab shows continued durable responses and meaningful survival patient outcomes in patients with metastatic MCC, exceeding the outcomes associated with cytotoxic chemotherapy. To view the presentation, please click here (Attachment no. 2)